

Apollo Tyres

Estimate change

TP change

Rating change



Bloomberg	APTY IN
Equity Shares (m)	635
M.Cap.(INRb)/(USD\$)	275.8 / 3.1
52-Week Range (INR)	585 / 368
1, 6, 12 Rel. Per (%)	-3/-2/-16
12M Avg Val (INR M)	749

Financials & valuations (INR b)

Y/E March	FY25	FY26E	FY27E
Sales	261.2	280.7	302.1
EBITDA	35.7	38.9	43.1
Adj. PAT	12.4	14.6	18.2
EPS (INR)	19.6	23.0	28.6
EPS Growth (%)	-33.2	17.6	24.1
BV/Share (INR)	290.1	304.8	329.9

Ratios

RoE (%)	8.7	9.7	11.2
RoCE (%)	11.4	12.6	14.5
Payout (%)	28.3	37.2	29.7
P/E (x)	22.2	18.9	15.2
P/BV (x)	1.5	1.4	1.3
Div. Yield (%)	1.2	1.6	2.0
FCF Yield (%)	4.0	7.3	6.8

Shareholding Pattern (%)

As On	Jun-25	Mar-25	Jun-24
Promoter	37.0	37.4	37.4
DII	29.1	28.1	26.7
FII	12.5	13.4	14.5
Others	21.5	21.1	21.5

FII includes depository receipts

CMP: INR434

TP: INR520 (+20%)

Buy

India business impresses; Europe disappoints

Margins likely to improve with a reduction in input costs

- Apollo Tyres (APTY)'s 1QFY26 consolidated performance was in line with our estimates. However, while standalone performance was much ahead of our estimates, the European business margin was weaker than expected.
- On account of its weak performance in Europe, we reduce our EPS estimates by 10%/6% over FY26/FY27E. We factor in a 60bp improvement in APTY's margin during our forecast period, driving a 21% PAT CAGR over a corrected base. Valuations at 15.2x FY27E appear attractive, especially when compared to peers. **We reiterate our BUY rating on APTY** with a TP of INR520 (valued at 18x Jun'27E consol. EPS).

India business impresses, but Europe disappoints

- APTYs' 1QFY26 consolidated performance was in line. However, while standalone performance was much ahead of our estimates, the European business was weaker than expected.
- Consolidated revenue grew ~4% YoY to INR65.6b (in line). Revenue was led by low to mid-single-digit growth in the replacement and OEM segments, offset by a decline in export volumes.
- The company's EBITDA margin remained flat YoY at 13.2% (in line). EBITDA contracted 4.6% YoY (up ~4% QoQ) to INR8.7b (in line).
- In 1Q, Apollo booked exceptional expenses related to the restructuring costs of INR3.7b at its Netherlands unit. Adjusted for these costs, PAT declined 15% YoY to INR2.8b (est. INR3.1b), primarily due to lower-than-expected other income.
- Standalone business revenue was in line at INR47.2b, up ~3% YoY and QoQ each. Gross margin contracted 380bp YoY (+220bp QoQ) to 36.7% (est. 35%). Employee costs experienced a sudden jump on account of new talent acquisition, bonus payouts, and a new ESOP scheme for senior management. EBITDA margin spiked 240bp QoQ (down 20bp YoY) to 13.6% (above our estimate of 12%), due to lower input costs.
- The EBITDA margin of the European business hit a multi-quarter low of 10.8% (down 290bp YoY) on account of weak demand and higher inflationary pressure, both on commodities and employees.
- Net debt during the period came down by INR3.9b to INR21b, with net debt/EBITDA improving to 0.7x, aided by controlled capex and a focus on free cash flow.

Highlights from the management commentary

- India business grew in line with the industry, with OE business growing at low single digits and the replacement segment growing at mid-single-digit levels. Management is hopeful of demand revival in the festive season. Revenue growth guidance remains at high single digits for FY26E.

- Europe witnessed a seasonal decline in revenue. Despite weak sentiments, APTY's PCLT segment outperformed the market. Management expects a pick-up in demand momentum in the coming quarters.
- Gross margin may improve in future quarters on account of reduced RM costs; however, exchange rate uncertainty remains a major factor to monitor.
- APTY refrained from providing margin guidance due to uncertain macroeconomic conditions. There is no change from the previous capex guidance of INR15b, which includes INR7b for maintenance and INR8b for expansion.

Valuation and view

On account of its weak performance in Europe, we reduce our EPS estimates by 10%/6% over FY26/FY27E. We factor in a 60bp improvement in APTY's margin during our forecast period, driving a 21% PAT CAGR over a corrected base. Valuations at 15.2x FY27E appear attractive, especially when compared to peers. **We reiterate our BUY rating on APTY** with a TP of INR520 (valued at 18x Jun'27E consol. EPS).

Cons - Qty Earnings Model

Y/E March	FY25				FY26E				FY25	FY26E	1QE	VAR
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4QE				
Net Revenues	63,349	64,370	69,280	64,236	65,608	69,317	74,982	70,771	261,234	280,677	67,102	-2
YoY Change (%)	1.4	2.5	5.0	2.6	3.6	7.7	8.2	10.2	2.9	10.6	5.9	
EBITDA	9,093	8,779	9,470	8,374	8,677	9,357	10,966	9,893	35,715	38,893	8,710	0
Margins (%)	14.4	13.6	13.7	13.0	13.2	13.5	14.6	14.0	13.7	13.9	13.0	
Depreciation	3,695	3,759	3,759	3,771	3,776	3,850	3,910	4,130	14,984	15,666	3,780	
Interest	1,070	1,197	1,105	1,094	1,006	950	880	876	4,466	3,712	1,010	
Other Income	308	217	81	275	189	230	120	250	881	789	370	
PBT before EO expense	4,636	4,040	4,686	3,785	4,085	4,787	6,296	5,137	17,146	20,305	4,290	
Extra-Ord expense	404	52	42	1,188	3,702	0	0	0	1,687	3,702	0	
PBT	4,232	3,988	4,644	2,596	383	4,787	6,296	5,137	15,460	16,603	4,290	
Tax Rate (%)	28.6	25.4	27.4	29.0	66.5	26.0	26.0	29.3	27.5	28.0	25.5	
MI & Profit/Loss of Asso. Cos.	0	-1	-2	-3	-1	-1	1	1	-7	0	0	
Reported PAT	3,020	2,975	3,372	1,846	129	3,544	4,658	3,629	11,213	11,959	3,197	
Adj PAT	3,313	3,012	3,403	2,708	2,812	3,544	4,658	3,629	12,436	14,626	3,197	-12
YoY Change (%)	-18.4	-37.6	-32.9	-41.8	-15.1	17.6	36.9	34.0	-33.2	17.6	-3.5	
Margins (%)	5.2	4.7	4.9	4.2	4.3	5.1	6.2	5.1	4.8	5.2	4.8	
Standalone (India)												
Net Revenues	45,916	44,617	45,398	45,805	47,254	47,294	48,576	49,587	181,736	192,711	48,212	-2
YoY Change (%)	4.0	1.2	4.8	4.4	2.9	6.0	7.0	8.3	3.6	6.0	5.0	
EBITDA	6,331	5,389	5,035	5,152	6,447	6,290	6,509	6,826	21,907	26,073	5,785	11
Margins (%)	13.8	12.1	11.1	11.2	13.6	13.3	13.4	13.8	12.1	13.5	12.0	
Adj PAT	2,264	1,675	1,251	1,438	2,233	2,244	2,407	2,602	6,657	9,492	1,978	13
YoY Change (%)	-27.1	-52.2	-59.2	-8.8	-1.4	34.0	92.4	81.0	-40.8	42.6	-12.6	
Europe (EUR m)												
Net Revenues	146	171	183	176	146	169	182	177	676	674	146	0
YoY Change (%)	1.4	1.2	4.0	-3.3	0.0	-1.2	-0.5	0.4	0.8	0.4	0.0	
Margins (%)	13.7	14.8	17.7	14.3	10.8	12.5	15.0	13.3	15.2	13.0	13.5	

Source: MOFSL Estimates



Highlights from the management commentary

Standalone update

- **Demand outlook:** India business grew in line with the industry, with OE business growing at low single digits and the replacement segment growing at mid-single digit levels. Also, while overall volume growth was flat YoY, it was up 4% QoQ.
- The CV OE growth was driven by increased pre-buying of trucks due to the mandate of AC cabins. Additionally, in PVs, they have secured an order to supply their premium Aspire 5 tyres to an auto manufacturer based out of Germany. Management is hopeful of demand revival in the festive season. Revenue growth guidance remains at high single digits for FY26E.
- **Revenue Mix:** Standalone revenue mix by product – TBR at 54%, PCR at 21%, farm specialty tyres at 7%, LCV at 8% and other specialty products at 9%. Replacement segment is still a major contributor, making up ~65% of revenue, followed by OEMs at 24% and export at 11%. India remains the primary focus, contributing 66% of consolidated revenue, Europe follows at 27%, and other geographies make up 7%.
- **Segmental trends and Market share:** In PV OEM, APTY lost market share due to certain key OEM accounts that they have walked away from in this quarter. They have performed broadly in line with the market in the replacement segment. In TBR replacement, the company has grown at mid-single digits, while in PCR replacement, APTY has grown slightly below the market at low single digits. The estimated market share in PCR stands at 20% and TBR replacement at 30%.
- **Exports** from India declined this quarter, primarily due to market conditions in Europe and the US.

Europe business update


- **Demand:** Europe witnessed a seasonal decline in revenue. Despite weak sentiments, APTY's PCLT segment outperformed the market. Management expects a pick-up in demand momentum in the coming quarters.
- The UHP mix for APTY has now increased to 48% for the quarter, reflecting continued premiumization.
- The key reason for margin contraction in Europe was inflationary pressure in a market where demand was challenging.
- Netherland plant to cease operations by summer 2026. One-time extraordinary restructuring cost was incurred this quarter (payout to employees working in that plant).
- While Hungary's average tax rate stands at 9%, the same in the Netherlands is about 20%. However, despite shifting operations from the Netherlands to Hungary, the average tax rate is unlikely to materially change, as they are headquartered in Hungary and they procure from the Netherlands and supply to different locations globally from Hungary.
- Reifencom booked Euro 53m in revenues, which was 5% up YoY, and an EBITDA margin of 4%.

Guidance:

- APTY refrained from providing margin guidance due to volatility in macroeconomic conditions. There is no change from the previous capex guidance of INR15b, which includes INR7b for maintenance and INR8b for expansion.
- Gross margin may improve in future quarters on account of reduced RM costs; however, exchange rate uncertainty remains a major factor to look out for.
- RoCE target remains at 15%. European operations pulled down the company's returns, but management is hopeful about recovery in the coming quarters.


Key exhibits

Exhibit 1: Consolidated revenue trend




Source: MOFSL, Company

Exhibit 2: Trend in APTY's India revenue




Source: MOFSL, Company

Exhibit 3: Performance trend in APTY's EU operations




Source: MOFSL, Company

Exhibit 4: Consolidated PAT and PAT growth trends




Source: MOFSL, Company

Exhibit 5: Trend in India's gross margin (%)



Source: MOFSL, Company

Exhibit 6: Trend in the EU's (derived) gross margin (%)



Source: MOFSL, Company

Valuation and view


- **India business well-placed for growth over the long term:** APTY is well placed with a strong competitive positioning and ready capacities to benefit from strong growth in TBR/PCR in OEM, as well as a recovery in the replacement segment. While the near-term OEM demand may remain subdued, we estimate a 5% volume CAGR over FY25-27, led by growth in the replacement demand as well as recovery in exports. After the correction in FY25, we expect margins to improve by over 160bp during FY25-27. Overall, after a sharp decline in earnings in FY25 (down 45% YoY), we expect standalone PAT to clock a 30% CAGR over FY25-27E.
- **Premiumization focus driving better brand positioning and a healthy margin profile:** The company has been focusing on enhancing its product offerings in both India and Europe. Benefiting from its robust R&D capabilities, the company saw notable enhancements in its sales mix, with the PV revenue contribution rising from 18% in FY18 to 23% in FY25, aligning with its premiumization strategy. In Europe, given the premium status of the Vredestein brand, coupled with the establishment of a cutting-edge manufacturing facility in Hungary, the company is well-positioned to enhance its product portfolio by shifting toward the lucrative premium car tyre segment. This is evident from the rising share of its UHP/UUHP mix in Europe to 48% in 3QFY25 from 43% in 3QFY24. With improved competitiveness, APTY has gained market share in the replacement segment and made inroads with OEMs. APTY's relentless focus on margin-lucrative segments would be the key margin tailwind in the coming years.
- **Leaner business model driving healthy returns:** The company has opted for smaller-scale capex plans rather than consolidating them, with an anticipated average annual capex of INR12b for FY25-27E, compared to INR27.2b during the previous capex cycle of FY18-20. These measures have contributed to the consistent generation of free cash flow over the past four years and a reduction in net debt to INR25b as of Mar'25 from INR43.5b in FY21. These measures, coupled with its premiumization strategy, have helped to drive improved returns over the years.
- **Valuation and view:** On account of its weak performance in Europe, we reduce our EPS estimates by 10%/6% over FY26/FY27E. We factor in a 60bp improvement in APTY's margin during our forecast period, driving a 21% PAT CAGR over a corrected base. Valuations at 15.2x FY27E appear attractive, especially when compared to peers. **We reiterate our BUY rating on APTY** with a TP of INR520 (valued at 18x Jun'27E consol. EPS).

Exhibit 7: Changes to our estimates

(INR M)	FY26E			FY27E		
	Rev	Old	Chg (%)	Rev	Old	Chg (%)
Net Sales	2,80,677	2,79,786	0.3	3,02,085	3,00,539	0.5
EBITDA	38,893	40,267	-3.4	43,052	44,287	-2.8
EBITDA (%)	13.9	14.4	-50bp	14.3	14.7	-50bp
EPS (INR)	23.0	25.5	-9.8	28.6	30.4	-6.0


Source: Company, MOFSL

Exhibit 8: One-year forward P/E



Source: MOFSL, Company


Exhibit 9: One-year forward P/B band



Source: MOFSL, Company


Story in charts

Exhibit 10: Revenue and growth trends




Source: Company, MOFSL

Exhibit 11: EBITDA and EBITDA margin trends




Source: Company, MOFSL

Exhibit 12: Revenue and growth trends for the EU business




Source: Company, MOFSL

Exhibit 13: EBITDA margin trend for APTY's EU business




Source: Company, MOFSL

Exhibit 14: PAT and PAT growth trends




Source: MOFSL, Company

Exhibit 15: Trend in APTY's return profile




Source: MOFSL, Company

Exhibit 16: FCF to remain positive due to lower capex



Source: MOFSL, Company

Exhibit 17: Net debt to be on a declining trend



Source: MOFSL, Company

Financials and valuations

Consolidated - Income Statement							(INR m)	
Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Total Income from Operations	163,502	172,820	209,476	245,681	253,777	261,234	280,677	302,085
Change (%)	-6.8	5.7	21.2	17.3	3.3	2.9	7.4	7.6
Raw Materials	90,756	93,945	123,855	146,371	136,631	146,945	155,939	167,273
Employees Cost	24,822	25,134	25,742	26,199	29,640	31,297	35,351	38,073
Other Expenses	28,537	26,917	34,137	39,975	42,519	47,276	50,494	53,687
Total Expenditure	144,115	145,995	183,735	212,545	208,790	225,519	241,784	259,033
% of Sales	88.1	84.5	87.7	86.5	82.3	86.3	86.1	85.7
EBITDA	19,387	26,825	25,741	33,137	44,987	35,715	38,893	43,052
EBITDA Margin (%)	11.9	15.5	12.3	13.5	17.7	13.7	13.9	14.3
growth	6.2	30.9	-20.8	9.8	31.4	-22.9	1.4	2.8
Depreciation	11,381	13,150	13,997	14,191	14,778	14,984	15,666	16,533
EBIT	8,006	13,675	11,744	18,945	30,209	20,732	23,227	26,519
EBIT Margin (%)	4.9	7.9	5.6	7.7	11.9	7.9	8.3	8.8
Int. and Finance Charges	2,808	4,430	4,444	5,312	5,059	4,466	3,712	2,743
Other Income	237	1,294	1,235	411	1,536	881	789	1,129
PBT bef. EO Exp.	5,434	10,539	8,535	14,044	26,685	17,146	20,305	24,905
EO Items	0	4,927	59	-226	1,786	1,687	3,702	0
PBT after EO Exp.	5,434	5,612	8,476	14,269	24,899	15,460	16,603	24,905
Total Tax	670	2,110	2,091	3,813	7,684	4,253	4,643	6,747
Tax Rate (%)	12.3	37.6	24.7	26.7	30.9	27.5	28.0	27.1
Reported PAT	4,764	3,502	6,385	10,456	17,219	11,213	11,959	18,158
Adjusted PAT	4,764	6,576	6,429	10,290	18,607	12,436	14,626	18,158
Change (%)	-42.8	38.1	-2.2	60.1	80.8	-33.2	17.6	24.1

Consolidated - Balance Sheet							(INR m)	
Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Equity Share Capital	572	635	635	635	635	635	635	635
Total Reserves	98,728	113,796	116,886	125,147	138,387	147,022	154,535	167,295
Net Worth	99,300	114,431	117,521	125,782	139,022	147,657	155,171	167,930
Total Loans	68,383	65,843	61,937	64,205	49,051	44,104	34,104	24,104
Deferred Tax Liabilities	7,032	7,020	9,014	12,590	16,530	17,988	17,988	17,988
Capital Employed	174,715	187,294	188,471	202,577	204,603	209,749	207,263	210,022
Gross Block	242,083	264,875	290,635	305,312	313,603	322,569	337,469	352,519
Less: Accum. Deprn.	89,734	102,883	116,880	131,071	145,850	160,833	176,499	193,032
Net Fixed Assets	152,350	161,992	173,755	174,241	167,753	161,736	160,970	159,487
Goodwill on Consolidation	2,134	2,204	2,158	2,288	2,311	2,374	2,374	2,374
Capital WIP	16,420	11,065	6,182	2,526	3,477	4,354	4,354	4,354
Total Investments	194	1,096	4,813	4,358	5,317	452	5,452	7,452
Curr. Assets, Loans&Adv.	60,957	82,088	84,550	90,117	90,716	104,144	103,279	110,797
Inventory	32,069	33,185	41,554	44,285	42,457	51,312	53,829	57,934
Account Receivables	9,399	13,808	20,513	24,885	26,648	30,621	32,297	34,760
Cash and Bank Balance	7,386	9,713	8,706	8,360	9,116	8,861	2,809	2,664
Loans and Advances	12,103	25,381	13,777	12,587	12,494	13,350	14,344	15,438
Curr. Liability & Prov.	57,340	71,151	82,987	70,953	64,971	63,311	69,166	74,442
Account Payables	23,090	28,067	35,309	33,956	29,786	28,744	30,759	33,105
Other Current Liabilities	29,115	38,644	44,193	33,505	31,427	30,168	33,681	36,250
Provisions	5,134	4,440	3,484	3,492	3,757	4,399	4,726	5,086
Net Current Assets	3,617	10,937	1,563	19,164	25,745	40,833	34,112	36,355
Appl. of Funds	174,715	187,294	188,471	202,577	204,603	209,749	207,263	210,022

Financials and valuations

Ratios

Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Basic (INR)								
EPS	8.3	10.4	10.1	16.2	29.3	19.6	23.0	28.6
<i>growth</i>	-42.8	24.3	-2.2	60.1	80.8	-33.2	17.6	24.1
Cash EPS	31.7	38.8	40.1	48.1	65.6	53.9	59.5	68.2
BV/Share	195.1	224.8	230.9	247.1	273.1	290.1	304.8	329.9
DPS	6.2	3.5	3.3	4.3	5.3	5.0	7.0	8.5
Payout (%)	90.5	63.5	32.3	25.8	19.4	28.3	37.2	29.7
Valuation (x)								
P/E	52.1	41.9	42.9	26.8	14.8	22.2	18.9	15.2
P/BV	2.2	1.9	1.9	1.8	1.6	1.5	1.4	1.3
EV/Sales	1.9	1.9	1.6	1.3	1.2	1.2	1.1	1.0
EV/EBITDA	16.0	12.4	12.8	10.0	7.0	8.7	7.9	6.9
Dividend Yield (%)	1.4	0.8	0.7	1.0	1.2	1.2	1.6	2.0
FCF per share	-5.0	20.3	5.3	21.6	43.5	17.2	31.5	29.7
Return Ratios (%)								
RoE	4.8	6.2	5.5	8.5	14.1	8.7	9.7	11.2
RoCE (pre-tax)	5.2	8.6	7.2	10.5	16.8	11.4	12.6	14.5
RoIC	4.8	5.4	5.3	7.8	11.2	7.9	8.6	9.9
Working Capital Ratios								
Fixed Asset Turnover (x)	0.7	0.7	0.7	0.8	0.8	0.8	0.8	0.9
Asset Turnover (x)	0.9	0.9	1.1	1.2	1.2	1.2	1.4	1.4
Inventory (Days)	72	70	72	66	61	72	70	70
Debtor (Days)	21	29	36	37	38	43	42	42
Creditor (Days)	52	59	62	50	43	40	40	40
Leverage Ratio (x)								
Net Debt/Equity	0.6	0.5	0.4	0.4	0.2	0.2	0.2	0.1

Consolidated - Cash Flow Statement

Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
(INR m)								
OP/(Loss) before Tax	5,434	5,612	8,477	14,272	25,402	15,466	20,305	24,905
Depreciation	11,381	13,150	13,997	14,191	14,778	14,984	15,666	16,533
Interest & Finance Charges	2,808	4,430	4,444	5,312	5,059	4,466	2,923	1,614
Direct Taxes Paid	-925	-2,035	-1,222	-2,168	-3,843	-3,926	-4,643	-6,747
(Inc)/Dec in WC	7,996	4,616	-1,829	-7,845	-5,031	-12,662	669	-2,388
CF from Operations	26,695	25,772	23,867	23,762	36,366	18,328	34,918	33,917
Others	-1,522	-1,303	-2,332	-2,396	-1,971	-97	0	0
CF from Operating incl EO	25,174	24,469	21,535	21,367	34,395	18,231	34,918	33,917
(Inc)/Dec in FA	-28,055	-11,563	-18,164	-7,627	-6,739	-7,306	-14,900	-15,050
Free Cash Flow	-2,881	12,906	3,371	13,739	27,656	10,926	20,018	18,867
(Pur)/Sale of Investments	-134	-12,547	5,960	2,512	-716	4,973	-5,000	-2,000
Others	230	667	482	331	348	310	789	1,129
CF from Investments	-27,959	-23,443	-11,722	-4,784	-7,107	-2,022	-19,111	-15,921
Issue of Shares	0	10,800	0	0	0	0	0	0
Inc/(Dec) in Debt	13,863	-3,222	-1,875	-7,484	-16,114	-5,218	-10,000	-10,000
Interest Paid	-2,232	-3,407	-4,022	-4,793	-4,759	-4,171	-3,712	-2,743
Dividend Paid	-4,310	0	-2,223	-2,064	-2,858	-3,811	-4,446	-5,398
Others	-1,771	-2,869	-2,712	-2,587	-2,802	-3,264	0	0
CF from Fin. Activity	5,550	1,302	-10,832	-16,928	-26,534	-16,464	-18,158	-18,142
Inc/Dec of Cash	2,765	2,327	-1,018	-346	755	-255	-2,350	-145
Opening Balance	4,622	7,387	9,725	8,706	8,361	9,115	8,861	6,511
Closing Balance	7,387	9,714	8,706	8,361	9,115	8,861	6,511	6,366

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://online.reports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered/qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Specific Disclosures

- 1 MOFSL, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- 2 MOFSL, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company
- 3 MOFSL, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months
- 4 MOFSL, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report
- 5 Research Analyst has not served as director/officer/employee in the subject company
- 6 MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- 7 MOFSL has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- 8 MOFSL has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months
- 9 MOFSL has not received any compensation or other benefits from third party in connection with the research report
- 10 MOFSL has not engaged in market making activity for the subject company

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)

- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal,

Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.